A Comparitive Study Between Mirabegron And Tamsulosin For Ureteric Stent Related Morbidity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030340

Enrollment

Registered

2021-01-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N201- Calculus of ureter

Interventions

Intervention1: Tablet Mirabegron 25mg HS OD for 14 days: patients are given Tablet mirabegron 25mg HS OD for 14 days Control Intervention1: Tablet Tamsulosin 0.4ug HS OD for 14 days: Patients are give

Eligibility

Inclusion criteria

Inclusion criteria: All patients undergoing uretero-renoscopic lithotripsy with double J stent placement as treatment for ureteric calculus

Exclusion criteria

Exclusion criteria: Patients with bilatral stone disease, urosepsis, pregnancy, uncontrolled hypertension and residual stones

Design outcomes

Primary

Measure	Time frame
Assessment of symptoms at baseline and at DJ stent removal after 2 weeksTimepoint: Assessment of symptoms at baseline and at DJ stent removal after 2 weeks	—

Secondary

Measure	Time frame
NIlTimepoint: NIL	—

Countries

India

Contacts

Public ContactAtif Abdullah C

MBBS., MS., MCh

dradkr@gmail.com8489972828

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026